Advanced Search

Study Preview



Study Title and Description

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.
Author Leung DH., Wirth S., Yao BB., Viani RM., Gonzalez-Peralta RP., Jonas MM., Lobritto SJ., Narkewicz MR., Sokal E., Fortuny C., Hsu EK., Del Valle-Segarra A., Zha J., Larsen L., Liu L., Shuster DL., Cohen DE., Rosenthal P.
Country Division of Gastroenterology, Hepatology, and Nutrition, Texas Children's Hospital and Department of Pediatrics Baylor College of Medicine Houston TX.
Year 2018
Numbers Pubmed ID: 30411078

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.